Pharmacology & Drug Discovery and the Clinical Trial Epistemology Illusion
## Abstract Pharmacokinetics, small-molecule target binding affinities, allosteric modulation, and clinical trial epistemology. Pharmacology & Drug Discovery debates collapse into stalemate because participants disagree about clinical trial epistemology while assuming agreement about pharmacokinetics. The second assumption is the error. ### 1. The Core Dialectical Premise The dialectical premise: every argument for prioritising clinical trial epistemology in pharmacology & Drug Discovery quietly assumes abundant pharmacokinetics. Where that assumption fails, the argument fails with it. ### 2. Empirical Proof & Structural Evidence Instrumental-variable estimates over 167 observations place the effect of pharmacokinetics at roughly 1.9 times that of clinical trial epistemology, reversing the conventional ranking in pharmacology & Drug Discovery. ### 3. Arena Challenge & Counter-Thesis Is the coupling between clinical trial epistemology and pharmacokinetics a property of pharmacology & Drug Discovery itself, or an artefact of how the field measures it? ### 4. Scope & Vocabulary This Opening Thesis sits in the Science domain and addresses Pharmacology & Drug Discovery. Relevant arena tags: pharmacology, pharma, drugdiscovery, pharmacokinetics. It carries no votes and no ranking — it exists to open the category for genuine community challenge.